Crossmark

Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study

Crossref DOI link: https://doi.org/10.1136/bmjdrc-2017-000469

Published Online: 2018-03-17

Published Print: 2018-03

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Shima, Kosuke Robert https://orcid.org/0000-0002-8523-6092
Ota, Tsuguhito

Kato, Ken-ichiro

Takeshita, Yumie

Misu, Hirofumi

Kaneko, Shuichi

Takamura, Toshinari https://orcid.org/0000-0002-4393-3244
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01337440 at ClinicalTrials.gov

Documents that mention this clinical trial

Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study
https://doi.org/10.1136/bmjdrc-2017-000469

nct01337440 at ClinicalTrials.gov

Documents that mention this clinical trial

Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study
https://doi.org/10.1136/bmjdrc-2017-000469

Document is current

Any future updates will be listed below